Johnson & Johnson (NYSE:JNJ) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 0.07% to $111.38. A federal jury in Dallas has returned a combined verdict of over $1 billion on behalf of six people who suffered serious medical complications caused by defective metal-on-metal hip implants made by Johnson & Johnson (JNJ) and its subsidiary DePuy Orthopaedics Inc.
The verdict comprises over $30 million in actual damages for the six plaintiffs and over $1 billion in punitive damages assessed against Johnson & Johnson and DePuy. The verdict is the third bellwether trial amid thousands of same court cases nationwide that have been consolidated in multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Texas. A bellwether trial is one that is typically representative of all the issues involved in the litigation of a mass tort case.
In March 2016, a Dallas jury awarded over $500 million to five individuals who suffered same physical and medical complications caused by the controversial Pinnacle hip implant. The share price of JNJ attracts active investors, as stock price of week volatility recorded 0.88%. The stock is going forward to its 52-week low with 21.48% and lagging behind from its 52-week high price with -10.45%.
Methode Electronics, Inc. (NYSE:MEI) [Trend Analysis] climbed reacts as active mover, shares a gain 0.95% to traded at $37.30 and the percentage gap among open changing to regular change was 0.27%. Methode Electronics, Inc. (NYSE: MEI) will release its second-quarter Fiscal 2017 results for the period ended October 29, 2016, on Thursday, December 8, 2016, before the market opens.
Following the release, the Firm will conduct a conference call and Webcast to review financial and operational highlights led by its President and Chief Executive Officer, Donald W. Duda, and Chief Financial Officer, John Hrudicka, at 10:00 a.m. Central time. The firm’s current ratio calculated as 4.60 for the most recent quarter.
The firm past twelve months price to sales ratio was 1.73 and price to cash ratio remained 5.53. As far as the returns are concern, the return on equity was recorded as 17.70% and return on investment was 15.80% while its return on asset stayed at 13.00%. The firm has total debt to equity ratio measured as 0.11.